Platelet rich plasma and diabetic foot ulcer healing

NewsBot · Jul 5, 2024

Clinical comprehensive treatment protocol for managing diabetic foot ulcers: A retrospective cohort study
Yan-Bin Wang et al
World J Clin Cases. 2024 Jun 16;12(17):2976-2982

Background: Diabetic foot ulcers (DFUs) are a common complication of diabetes, often leading to severe infections, amputations, and reduced quality of life. The current standard treatment protocols for DFUs have limitations in promoting efficient wound healing and preventing complications. A comprehensive treatment approach targeting multiple aspects of wound care may offer improved outcomes for patients with DFUs. The hypothesis of this study is that a comprehensive treatment protocol for DFUs will result in faster wound healing, reduced amputation rates, and improved overall patient outcomes compared to standard treatment protocols.

Aim: To compare the efficacy and safety of a comprehensive treatment protocol for DFUs with those of the standard treatment protocol.

Methods: This retrospective study included 62 patients with DFUs, enrolled between January 2022 and January 2024, randomly assigned to the experimental (n = 32) or control (n = 30) group. The experimental group received a comprehensive treatment comprising blood circulation improvement, debridement, vacuum sealing drainage, recombinant human epidermal growth factor and anti-inflammatory dressing, and skin grafting. The control group received standard treatment, which included wound cleaning and dressing, antibiotics administration, and surgical debridement or amputation, if necessary. Time taken to reduce the white blood cell count, number of dressing changes, wound healing rate and time, and amputation rate were assessed.

Results: The experimental group exhibited significantly better outcomes than those of the control group in terms of the wound healing rate, wound healing time, and amputation rate. Additionally, the comprehensive treatment protocol was safe and well tolerated by the patients.

Conclusion: Comprehensive treatment for DFUs is more effective than standard treatment, promoting granulation tissue growth, shortening hospitalization time, reducing pain and amputation rate, improving wound healing, and enhancing quality of life.
Click to expand...

NewsBot · Sep 28, 2024

Efficacy and safety of autologous whole blood clot in diabetic foot ulcers: a randomised controlled trial
Robert Snyder et al
J Wound Care. 2024 Sep 2;33(9):688-700

Objective: Diabetic foot ulcers (DFUs) present a significant global health challenge, resulting in high morbidity and economic costs. Current available treatments often fail to achieve satisfactory healing rates, highlighting the need for novel therapies. This study evaluated the safety and efficacy of a novel autologous whole blood clot (AWBC)-a blood-based, biodegradable provisional matrix-in conjunction with standard of care (SoC) when compared to SoC alone in the treatment of hard-to-heal DFUs.

Method: A multicentre, prospective, blinded assessor, randomised controlled trial was conducted at 16 sites across the US, South Africa and Turkey. A cohort of patients with hard-to-heal DFUs was enrolled and randomised to either the AWBC group or the control group. The primary endpoint was complete wound closure at 12 weeks, while secondary endpoints included time to heal and percentage area reduction (PAR) at four and eight weeks. Data were analysed using both intention-to-treat (ITT) and per-protocol (PP) populations.

Results: The cohort included 119 patients. AWBC treatment resulted in a significantly higher healing rate compared to the control in both ITT (41% versus 15%, respectively; p=0.002) and PP populations (51% versus 18%, respectively; p=0.0075). AWBC treatment also resulted in a shorter mean time to heal and higher durability of wound closure. Safety analysis showed a similar incidence of adverse events (AEs) between groups, with no device-related AEs.

Conclusion: The AWBC system, by modulating the wound microenvironment and providing a functional extracellular matrix, offered a promising new approach to treating hard-to-heal DFUs, demonstrating superior healing outcomes compared to SoC alone in this study.
Click to expand...

NewsBot · Nov 15, 2024

Platelet-rich plasma promotes wound repair in diabetic foot ulcer mice via the VEGFA/VEGFR2/ERK pathway
Weiqiang Wei et al
Growth Factors. 2024 Nov 14:1-10

Diabetic foot ulcers (DFUs) are a severe microvascular complication. Platelet-rich plasma (PRP) pitches in DFU treatment. This study explored the mechanism of PRP facilitating wound repair in DFU mice via vascular endothelial growth factor A (VEGFA)/VEGF receptor 2 (VEGFR2)/extracellular signal-regulated kinase (ERK) pathway. The DFU mouse model was established, with wound skin injected with PRP, followed by the detections of wound area, histopathological changes, and CD31-positive cells. IL-6/TNF-α/VEGFA/VEGFR2/p-VEGFR2/(ERK1/2)/(p-ERK1/2) levels in wound tissue homogenates were assessed. VEGFA-VEGFR2 interaction was evaluated. PRP-treated DFU mice were simultaneously treated with fruquintinib/PD98059. PRP reduced wound area, IL-6 and TNF-α levels, elevated epidermal dermal thickness, CD31-positive cell number, and aligned tissue structure, which were mitigated by fruquintinib/PD98059. PRP promoted VEGFR2 phosphorylation. PRP and fruquintinib/PD98059 abated p-VEGFR2/VEGFR2 or p-ERK1/2/ERK1/2 levels in DFU mice. PRP activated the ERK pathway through VEGFA/VEGFR2. Collectively, PRP promoted VEGFR2 phosphorylation and activated the ERK pathway, thereby facilitating wound repair in DFU mice.
Click to expand...

NewsBot · Nov 24, 2024

Platelet-Rich Plasma in the Treatment of Diabetic Foot Ulcers
Gomez, Paul T. BS; Andrews, Karen L. MD; Arthurs, Jennifer R. APRN; Bruce, Alison J. MB, ChB; Wyles, Saranya P. MD, PhD
Author Information
Advances in Skin & Wound Care 37(11&12)

BACKGROUND
Chronic nonhealing neuropathic foot ulcers affect approximately 15% to 30% of patients with diabetes mellitus and are associated with significant morbidity and mortality. Although current strategies to address these chronic wounds include a multifactorial approach, clinical outcomes remain poor and warrant improvement. Platelet-rich plasma (PRP), derived from autologous or allogeneic blood, is an emerging regenerative product that aims to serve as an adjuvant to standard diabetic foot ulcer (DFU) treatment.

OBJECTIVE
To examine controlled clinical trials investigating the efficacy of platelet-rich therapies in promoting healing of chronic DFUs.

DATA SOURCES
The PubMed/MEDLINE database.

STUDY SELECTION
Researchers selected 11 controlled clinical trials published between 2011 and 2021 that investigated the efficacy of PRP treatments for chronic DFUs.

DATA EXTRACTION
Extracted data included study type and size, participant sex and age, duration of diabetes, glycated hemoglobin levels, baseline ulcer area, wound duration, healing parameters, PRP preparation approach, and application type.

DATA SYNTHESIS
Randomized prospective studies (n = 8), prospective controlled studies (n = 2), and a double-blind, randomized controlled study (n = 1) were included in the review. In general, PRP plus standard of care provided superior wound healing, in both percentage of wound closure and healing rate, compared with standard of care alone.

CONCLUSIONS
Use of PRP as an adjuvant for healing chronic DFUs appears to improve wound healing. Further research on optimizing PRP preparation and exploring combinatorial approaches will be important in advancing this avenue for chronic wound healing.
Click to expand...

NewsBot · Dec 19, 2024

Platelet-Rich Plasma in Diabetic Foot Ulcer Healing: Contemplating the Facts
Jacob Smith, Vikrant Rai
Int J Mol Sci. 2024 Nov 29;25(23):12864

Diabetic foot ulcers (DFUs), debilitating complication of diabetes, often lead to amputation even in the presence of current advanced treatment for DFUs. Platelet-rich plasma (PRP) containing growth factors and other proteins has been suggested as a potent therapeutic in promoting DFU healing. PRP is safe and effective in improving the DFU healing rate, decreasing healing time, and making chronic wounds viable for treatment. Though PRP is safe and effective in promoting DFU healing, there are inconsistencies in clinical outcomes. These varying results may be due to various concentrations of PRP being used. Most studies report dosage and timing, but none have reported the concentration of various factors. This is important, as the concentration of factors in PRP can vary significantly with each preparation and may directly impact the healing outcome. This critical review discusses the limiting factors and issues related to PRP therapy and future directives. A systematic search of PubMed and Google Scholar was performed with keywords including diabetic foot ulcer, ulcer healing, platelet-rich plasma, DFU treatment, and PRP limitations and efficacy, alone or in combination, to search the related articles. The articles describing DFU and the use of PRP in DFU healing were included. The existing literature suggests that PRP is effective and safe for promoting DFU healing, but larger clinical trials are needed to improve clinical outcomes. There is a need to consider multiple factors including the role of epigenetics, lifestyle modification, and the percentage composition of each constituent in PRP.
Click to expand...

NewsBot · Apr 4, 2025

Platelet-Rich Plasma in the Treatment of Diabetic Foot Ulcers
Paul T Gomez et al
Adv Skin Wound Care. 2024 Nov-Dec;37(11&12):608-615

Background: Chronic nonhealing neuropathic foot ulcers affect approximately 15% to 30% of patients with diabetes mellitus and are associated with significant morbidity and mortality. Although current strategies to address these chronic wounds include a multifactorial approach, clinical outcomes remain poor and warrant improvement. Platelet-rich plasma (PRP), derived from autologous or allogeneic blood, is an emerging regenerative product that aims to serve as an adjuvant to standard diabetic foot ulcer (DFU) treatment.

Objective: To examine controlled clinical trials investigating the efficacy of platelet-rich therapies in promoting healing of chronic DFUs.

Data sources: The PubMed/MEDLINE database.

Study selection: Researchers selected 11 controlled clinical trials published between 2011 and 2021 that investigated the efficacy of PRP treatments for chronic DFUs.

Data extraction: Extracted data included study type and size, participant sex and age, duration of diabetes, glycated hemoglobin levels, baseline ulcer area, wound duration, healing parameters, PRP preparation approach, and application type.

Data synthesis: Randomized prospective studies (n = 8), prospective controlled studies (n = 2), and a double-blind, randomized controlled study (n = 1) were included in the review. In general, PRP plus standard of care provided superior wound healing, in both percentage of wound closure and healing rate, compared with standard of care alone.

Conclusions: Use of PRP as an adjuvant for healing chronic DFUs appears to improve wound healing. Further research on optimizing PRP preparation and exploring combinatorial approaches will be important in advancing this avenue for chronic wound healing.
Click to expand...

NewsBot · May 6, 2025

Platelet concentrates in diabetic foot ulcers: A comparative review of PRP, PRF, and CGF with case insights
Mengling Yang et al
Regen Ther. 2025 Feb 21:28:625-632.

Diabetic foot ulcers (DFUs) are severe complications of diabetes, often leading to chronic wounds, amputations, and increased mortality risk. Platelet concentrates (PCs)-natural biomaterials utilized in regenerative medicine-have garnered attention for their capacity to enhance tissue repair and wound healing. This study reviews the preparation methods, biological mechanisms, and clinical efficacy of three generations of PCs: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and concentrated growth factors (CGF). Comparative analysis reveals that PRP, the first generation, provides abundant growth factors but relies on anticoagulants, which may hinder fibrin formation and tissue adhesion. PRF, as the second generation, eliminates anticoagulants, forming a fibrin matrix that sustains growth factor release and enhances cell migration. CGF, the latest advancement, employs refined centrifugation to achieve higher growth factor concentrations and a denser fibrin matrix, accelerating tissue regeneration. Case series results demonstrated superior wound healing outcomes with CGF, including faster epithelialization and reduced healing time compared to PRP and PRF. These findings underscore CGF's potential as the most effective PC for managing DFUs, supporting its broader clinical adoption in advanced wound care.
Click to expand...

NewsBot · Jun 5, 2025

Platelet-rich plasma as a potential antimicrobial agent against multidrug-resistant bacteria in diabetic foot infections
Engy Aboelsaad et al
Sci Rep. 2025 Apr 30;15(1):15145

Diabetes mellitus is a global public health concern, with diabetic foot infections (DFIs) being common clinical complications among affected patients. Bacterial isolates resistant to commonly used antimicrobial drugs are becoming more prevalent in DFIs. Some research suggests that platelet-rich plasma (PRP) may inhibit bacterial growth, making it a promising biological therapy. Therefore, an in vitro experimental study was conducted on 53 multidrug-resistant (MDR) bacterial strains isolated from DFIs. The isolates were methicillin-resistant Staphylococcus aureus (MRSA), MDR Klebsiella pneumoniae, and MDR Pseudomonas aeruginosa. The antibacterial activity of PRP was assessed using Kirby-Bauer disk diffusion method, broth microdilution method, checkerboard synergy testing, and time-kill assay. The time-kill assay demonstrated that PRP's antibacterial efficacy peaked during the second hour of incubation for MRSA and Pseudomonas aeruginosa, but peaked at the first hour for Klebsiella pneumoniae. However, the PPR's efficiency against all isolates decreased after the peak point, with no antibacterial activity observed at the 24th h of incubation. Additionally, biofilm inhibition and eradication assays revealed that PRP has no effect on biofilm formation. As a result, PRP has the ability to inhibit bacterial growth, although this effect is transient and depends on the bacterial strain.
Click to expand...

NewsBot · Jun 19, 2025

Cost-Effectiveness Analysis for Managing Diabetic Foot Ulcer (DFU) in USA: Platelet-Rich Plasma (PRP) vs Standard of Care (SoC)
Salvatore Russo et al
Clinicoecon Outcomes Res. 2025 Mar 8:17:157-169.

Purpose: Chronic skin ulcers in diabetic foot patients are a significant health concern. Diabetic foot ulcers (DFUs) significantly threaten the health and longevity of individuals with diabetes, leading to severe complications like infection and amputation and contributing to high morbidity and mortality rates. Given the severe implications, practical strategies to prevent and manage DFUs are crucial to reducing amputation rates. Platelet-rich plasma (PRP) has emerged as a popular treatment option due to its properties that mimic the body's natural healing process. The objective of the study was to evaluate the cost-effectiveness of PRPR vs standard of care in US context.

Methods: Decision analytical model was used to synthesize clinical and economic parameters. In detail a CEA analysis was employed using a Markov decision-making model to evaluate patients with chronic DFUs lasting over three weeks and at high risk for orthopedic complications. The study assessed the effectiveness of different treatments, measured in quality-adjusted life years (QALYs), and reported costs in 2023 dollars using a micro-costing approach alongside a clinical trial.

Results: The study concluded that PRP gel is a cost-effective treatment for non-healing DFUs, resulting in lower care costs over one year compared to other treatments and cost savings over five years.

Conclusion: Thus, PRP treatment is a promising and practical option, improving patient outcomes and reducing healthcare costs. It is an attractive choice for healthcare providers and insurers in managing non-healing diabetic foot ulcers.
Click to expand...

NewsBot · Jul 2, 2025

Efficacy and safety of platelet-rich plasma versus conventional care in diabetic foot ulcers: a meta-analysis of randomized controlled trials
Hongyan Xu et al
Acta Diabetol. 2025 Jul 2.

Purpose: This meta-analysis aims to assess the efficacy and safety of platelet-rich plasma (PRP) through topical application and local injection methods compared to conventional care in patients with diabetic foot ulcers (DFU).

Methods: A comprehensive literature search was conducted across PubMed, Embase, and Web of Science databases up to November 2024. Randomized controlled trials evaluating the efficacy and safety of PRP versus conventional care in DFU patients were included. Pooled weighted mean differences (WMD) and risk ratios (RR) were calculated with 95% confidence intervals.

Results: Fifteen randomized controlled trials (1,010 patients) were included. The PRP group showed significantly improved complete healing rates compared to conventional care (RR: 1.53, 95% CI: 1.39-1.58, P < 0.001), with comparable effectiveness between topical application and local injection methods (P = 0.57). Notably, PRP demonstrated a shorter healing time compared to conventional care (WMD: -19.48 days, 95% CI: -27.91 to -11.05, P < 0.001). The PRP group exhibited lower wound infection rates and amputation rates (RR: 0.51, 95% CI: 0.35 to 0.75, P < 0.001; RR: 0.45, 95% CI: 0.26 to 0.79, P = 0.005). The PRP group did not lead to a higher incidence of treatment-related adverse events compared to conventional care (RR: 0.80, 95% CI: 0.05 to 12.30, P = 0.87).

Conclusions: This meta-analysis confirms that PRP application, both topically and via local injection, improves the complete healing rate, reduces healing time, infection rates, and amputations, without increasing adverse events. These findings support the integration of PRP into clinical practice for the management of diabetic foot ulcers.
Click to expand...

Platelet rich plasma and diabetic foot ulcer healing

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Platelet-rich plasma for plantar warts

Platelet rich plasma for sesamoid injuries

Platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis

Intraoperative use of Platelet-Rich Plasma

Platelet rich plasma vs shock wave vs corticosteroids for plantar fasciitis

Platelet-rich plasma in treatment of chronic venous leg ulcers

Platelet rich plasma for plantar plate injuries

Share This Page

Platelet rich plasma and diabetic foot ulcer healing

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Platelet-rich plasma for plantar warts

Platelet rich plasma for sesamoid injuries

Platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis

Intraoperative use of Platelet-Rich Plasma

Platelet rich plasma vs shock wave vs corticosteroids for plantar fasciitis

Platelet-rich plasma in treatment of chronic venous leg ulcers

Platelet rich plasma for plantar plate injuries

Share This Page

Useful Searches